Clinical Trial Update: Study on the Prevention of Dermal Toxicity Caused by Regorafenib by Traditional Chinese Medicine TDX105 [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating TDX105 (traditional Chinese medicine) to prevent dermal toxicity caused by regorafenib in patients with advanced colorectal ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Regorafenib (regorafenib)
• TDX105

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Hand and Foot Skin Reaction, Colorectal Cancer Stage IV | Phase 2 | Status: UNKNOWN